The closing price of Arcus Biosciences Inc. (NYSE: RCUS) was $19.90 for the day, down -3.26% from the previous closing price of $20.57. In other words, the price has decreased by -$0.67 from its previous closing price. On the day, 706667 shares were traded. RCUS stock price reached its highest trading level at $20.51 during the session, while it also had its lowest trading level at $19.75.
Our analysis of RCUS’s different ratios will help us gain a deeper understanding of the company. For the most recent quarter (mrq), Quick Ratio is recorded 5.50 and its Current Ratio is at 5.50. In the meantime, Its Debt-to-Equity ratio is 0.00 whereas as Long-Term Debt/Eq ratio is at 0.00.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, BofA Securities on November 18, 2022, initiated with a Neutral rating and assigned the stock a target price of $33.
Also, insider trades can serve as a great indicator of what management thinks about the future direction of a stock’s price. A recent insider transaction in this stock occurred on Jul 28 when Jarrett Jennifer sold 45,000 shares for $20.25 per share. The transaction valued at 911,250 led to the insider holds 336,566 shares of the business.
Azoy Alexander sold 1,018 shares of RCUS for $20,777 on Jul 03. The Chief Accounting Officer now owns 11,596 shares after completing the transaction at $20.41 per share. On Jun 28, another insider, GILEAD SCIENCES, INC., who serves as the 10% Owner of the company, bought 1,010,000 shares for $19.26 each. As a result, the insider paid 19,452,600 and bolstered with 14,823,029 shares of the company.
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, RCUS now has a Market Capitalization of 1.48B and an Enterprise Value of 553.04M. For the stock, the TTM Price-to-Sale (P/S) ratio is 12.04 while its Price-to-Book (P/B) ratio in mrq is 2.57. Its current Enterprise Value per Revenue stands at 4.57 whereas that against EBITDA is -2.01.
Stock Price History:
Over the past 52 weeks, RCUS has reached a high of $36.13, while it has fallen to a 52-week low of $15.70. The 50-Day Moving Average of the stock is 20.22, while the 200-Day Moving Average is calculated to be 20.39.
RCUS traded an average of 925.48K shares per day over the past three months and 676.07k shares per day over the past ten days. A total of 73.20M shares are outstanding, with a floating share count of 52.64M. Insiders hold about 0.90% of the company’s shares, while institutions hold 74.30% stake in the company. Shares short for RCUS as of Aug 30, 2023 were 7.34M with a Short Ratio of 7.34M, compared to 7.24M on Jul 30, 2023. Therefore, it implies a Short% of Shares Outstanding of 9.85% and a Short% of Float of 16.60%.
The firm’s stock currently is rated by 11 analysts. On average, analysts expect EPS of -$1.14 for the current quarter, with a high estimate of -$1.04 and a low estimate of -$1.23, while EPS last year was -$0.9. The consensus estimate for the next quarter is -$1.14, with high estimates of -$0.93 and low estimates of -$1.31.
Analysts are recommending an EPS of between -$3.79 and -$4.64 for the fiscal current year, implying an average EPS of -$4.3. EPS for the following year is -$3.76, with 10 analysts recommending between -$1.17 and -$5.71.
It is expected that $90B in revenue will be generated in the current quarter, according to 9 analysts. It ranges from a high estimate of $36.64M to a low estimate of $22.5M. As of the current estimate, Arcus Biosciences Inc.’s year-ago sales were $21.89M, an estimated increase of 24.60% from the year-ago figure. For the next quarter, 8 analysts are estimating revenue of $25.36M, a decrease of -25.40% less than the figure of $24.60% in the same quarter last year. There is a high estimate of $30M for the next quarter, whereas the lowest estimate is $20M.
A total of 11 analysts have provided revenue estimates for RCUS’s current fiscal year. The highest revenue estimate was $144M, while the lowest revenue estimate was $97.7M, resulting in an average revenue estimate of $110.76M. In the same quarter a year ago, actual revenue was $112M, down -1.10% from the average estimate. Based on 10 analysts’ estimates, the company’s revenue will be $180.36M in the next fiscal year. The high estimate is $347.7M and the low estimate is $90M. The average revenue growth estimate for next year is up 62.80% from the average revenue estimate for this year.